

Addressing an Underutilized Best Practice for Severe and Persistent Mental Illness: Long-Acting Injectables

TREATMENT CHALLENGES

People with severe and persistent mental illness (SPMI) are at significant risk for relapse and psychiatric hospitalization, primarily related to non-adherence of prescribed oral medications. The resulting periods of destabilization adversely impact emotional, social, legal and financial well-being. Several studies have demonstrated that long-acting injectable antipsychotics (LAI-AP) improve recovery and community tenure.¹²³⁴⁵ As with many behavioral health interventions and developing science, additional research is called for to further substantiate these findings.^{6 7}

The individual and societal costs of SPMI conditions are significant. For schizophrenia spectrum disorders, individuals may experience a complex array of issues, including positive, negative and mood symptoms; medical and substance use comorbidities; and cognitive dysfunction that significantly impair social and occupational functioning. Internationally, schizophrenia is a leading cause of years lost to disability, particularly impacting adolescents and young adults.⁸ Treatment of schizophrenia conditions aims to improve functioning and recovery across the lifespan, but symptom-reduction and relapse-prevention are important interim goals as well. Evidence-based practices incorporate antipsychotic medications that reduce psychotic symptoms and greatly decrease the risk of relapse. However, medication effectiveness is dramatically decreased by non-adherence.⁹ A meta-analysis of studies found that non-adherence is prevalent in an average of 41 percent of participants.¹⁰ Prescribers are often unaware of this issue and generally overestimate medication adherence.¹¹ Studies also indicate that as little as a 10-day lapse in medication refills can result in a doubling of inpatient admission rates.¹²

BEACON'S POSITION STATEMENT

Long-acting injectable antipsychotic (LAI-AP) medications represent an underutilized treatment intervention for people with severe and persistent mental illness (such as schizophrenia, schizoaffective disorder and bipolar disorder). **As an evidence-based clinical approach, Beacon Health Options (Beacon) strongly recommends that psychiatric prescribers use a shared decision-making process and systematically offer an LAI-AP as a first-line treatment to most individuals who require long-term antipsychotic treatment.** For non-adherent individuals with historically higher levels of risk, additional structural support may be required, such as Medication over Objection (court-ordered medication statutes in 45 states and D.C.)¹³ or Assertive Community Treatment (ACT), to ensure continuous medication adherence and community-based tenure.^{14 15} This clinical position paper outlines the rationale for appropriate use and expansion of LAI-AP as an evidence-based treatment.

EXPLANATION OF TERMS

- **First-Generation Antipsychotic (FGA):** Initial drugs developed in the 1950s to manage the symptoms of psychosis, delivered orally
- **Second-Generation Antipsychotic (SGA):** Developed in the 1980s to manage the symptoms of psychosis and to address extrapyramidal side effects of FGAs, delivered orally; metabolic syndrome side-effect issues should be closely monitored for SGAs.
- **Long-Acting Injectable (LAI) Antipsychotic Drugs:** First developed in 1966 as an FGA long-acting medication for psychosis, administered intramuscularly (IM) with a one- to four-week effective period. SGA LAI was first introduced in 2001.
 - » **FGA LAI**—Haldol Decanoate (Haloperidol), Prolixin Decanoate (Fluphenazine)
 - » **SGA LAI**—Risperdal Consta (Risperidone), Invega Sustenna/Trinza (Paliperidone), Zyprexa Relprevv (Olanzapine pamoate), Abilify Maintena (Aripiprazole), Aristada (Aripiprazole lauroxil)
- **Severe and Persistent Mental Illness (SPMI):** Impacting 9.8 million American adults (4.1 percent of all adults).¹⁶ The most significant SPMI conditions include schizophrenia, schizoaffective disorder and bipolar disorder. These conditions impair multiple facets of functioning with substantial disease burden on individuals, relatives and friends, the health care system, and society. Often emerging in late adolescence or early adulthood, these conditions contribute to marked impairments in vocational and social activities.

CONSIDERATIONS FOR SELECTING LAI-APS

LAI-APs have demonstrated effectiveness in treating schizophrenia and other severe psychotic disorders. They ensure stable blood levels, leading to reduced risk of relapse. Newer LAI-APs offer additional advantages as they are easier to dose optimally, produce fewer side effects, and fit well with integrated rehabilitation programs. To provide integrated treatment, including medication management, it is important to address psychosocial needs as well as incorporate personal preferences whenever possible within the person-centered care plan.¹⁷ Intensive care coordination helps to address secondary considerations related to LAI-AP adherence, including transportation, scheduling, condition education, access to community support resources, and provider coordination.¹⁸

LAI-AP ADVANTAGES OVER ORAL ALTERNATIVES	CONSIDERATIONS TO BE ADDRESSED WHEN USING LAI-AP
<ul style="list-style-type: none"> • Daily administration unnecessary, simplified decision process (members typically prefer once established) • Immediate notification of non-adherence with administration transparency^{19,20} and 'natural alerts' if individuals fail to take their medication²¹ • Less probability for rebound symptoms and rapidly occurring/abrupt relapses • Overcome partial adherence or overt non-adherence • If a relapse occurs, non-adherence can likely be ruled out²² • Reduced risk of unintentional or deliberate overdose²³ • Lower relapse rates^{24,25,26} • Minimal gastrointestinal absorption problems, circumventing first-pass metabolism²⁷ • More consistent bio-availability²⁸ • More predictable correlation between dosage and plasma levels²⁹ and reduced peak-trough plasma levels³⁰ • Improved outcomes³¹ • Improved individual and physicians' satisfaction³² • Promotion of regular contact with the mental health care team³³ 	<ul style="list-style-type: none"> • Continuity of LAI treatment started in inpatient setting and continued in outpatient community can be further assisted by Beacon care coordination and medication manufacturer resources³⁴ • Slow dose titration,^{35,36} longer time to achieve steady state levels,³⁷ and delayed disappearance of distressing and/or severe side effects with less flexibility of dose adjustment³⁸ requiring advance planning for effective administration • Pain at the injection site can occur, and leakage into the subcutaneous tissue and/or the skin may cause irritation and lesions (especially for 'oily' long-acting injectable) • Transport to outpatient clinics may be necessary or home visits by community nurses for their administration • Risperidone long-acting injectable needs refrigeration • Perception of stigma, requiring education and peer support • Price differentials, possible subsidy needed

To address prescriber concerns regarding continued outpatient management of LAI-APs, prior authorization requirements, and cost issues, Beacon provides care coordination services in conjunction with manufacturer and community-based resources to promote continuous care. To ensure the availability of providers able to administer LAIs, Beacon coordinates psychiatric consultation for primary care physicians serving individuals with stabilized medication protocols. Beacon expects in-network facility providers to offer LAI-AP interventions as a standard evidence-based treatment option for appropriate inpatient cases. In turn, Beacon supports care coordination resources to address continuity of care concerns following LAI-AP initiation and subsequent transition to community-based care.

SUMMARY OF KEY LAI-AP TREATMENT TAKEAWAYS

LAI-APs should be considered for individuals with heightened risk factors, including non-adherence, severe symptoms, comorbid substance use, cognitive impairment, ambivalence or negative attitudes towards medications and poor insight.³⁹ Research to date has not fully demonstrated an overall effectiveness advantage of newer (SGA) LAIs over older LAIs.^{40,41} Therefore, clinicians should consider each person's preferences, prior experience with antipsychotics, health status and the specific side-effect profiles of the medications when selecting an LAI-AP.^{42,43} Because LAI-AP dosages are not immediately changeable to adjust for side effects, LAIs may need to follow an initial course of oral medications. This approach is to accommodate dose regulation for those individuals not previously prescribed antipsychotic medications. Because people experiencing recent-onset psychosis are particularly sensitive to side effects, this factor should be considered in the medication selection. The following consensus-based guideline summarizes key LAI-AP practice decisions and adherence tips:⁴⁴

1. LAI-APs are recommended for individuals with schizophrenia, schizoaffective disorder, and bipolar disorder.
 - Based on individual treatment response and medication history, either second-generation antipsychotics (SGA) or first-generation antipsychotics (FGA) LAI-APs may be used after the first episode of schizophrenia.⁴⁵
 - First-generation LAI-APs (depot neuroleptics) must be avoided for bipolar disorder conditions.

2. Although LAI-AP antipsychotics have long been viewed as a treatment for a small subgroup of individuals with non-adherence issues, frequent relapses or who pose a risk to others, LAI-APs should be considered and systematically proposed when maintenance antipsychotic treatment is indicated.
3. According to their efficacy and tolerability, second-line LAI-AP SGAs are recommended as a monotherapy to prevent manic recurrence or in combination with a mood stabilizer to prevent depressive recurrence in the maintenance treatment of bipolar disorder.
4. Shared decision-making improves the acceptance and understanding of the benefits of an LAI-AP, providing individualized information concerning the advantages and inconveniences of the LAI-AP formulation. Intensive care coordination should be incorporated to support adherence as needed.
5. When switching to an LAI antipsychotic, consider two scenarios:
 - Switch from an oral antipsychotic
 - » Prescribe the oral formulation of the antipsychotic to establish tolerability/efficacy
 - » Use an initial dose of the LAI antipsychotic equivalent to the oral form
 - Switch from another LAI antipsychotic
 - » Use several test doses of the oral formulation of the LAI antipsychotic if the individual has never taken this medication previously (to rule out hypersensitivity)
 - » Introduce the new LAI antipsychotic at the scheduled period of the next injection
 - » Use an initial dose of the LAI antipsychotic equivalent to the previous LAI
6. Medication administration
 - Provider reminders to member regarding injection date to improve adherence
 - » First line: phone call and diary
 - » Second line: letter or text message
 - » Coordinate the dates of medical consultations with the scheduled dates of LAI antipsychotic injections
 - Prevent local LAI-AP administration complications
 - » Utilize competent/trained professionals (nurse, psychiatrist, GP)
 - » Check the length of needle and penetrate the deep muscle tissue⁴⁶
 - » Select the injection site according to individual preference
 - » Propose systematically a local anesthetic to reduce pain at the injection site
 - » Permit the change of the injection site for each injection, as needed

As an evidence-based clinical approach, Beacon strongly recommends that psychiatric prescribers use a shared decision-making process and systematically offer an LAI-AP as a first-line treatment to most individuals who require long-term antipsychotic treatment.

REFERENCES

- ¹ Patel MX & David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? *Advances in Psychiatric Treatment*, 2005;11:203-213
- ² Lang K, Meyers JL, et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. *Psychiatr Serv*, 2010;61(12):1239-1247
- ³ Subotnik KL, Casaus LR, Ventura J, Luo JS, Helleman GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia - A Randomized Clinical Trial. *JAMA Psychiatry*. 2015;72(8):822-829. doi:10.1001/jamapsychiatry.2015.0270. Published online June 24, 2015.
- ⁴ Tiihonen J, Mittendorfer-Rutz, E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enksson D, Leval A, Sermon J, Tanskanen A, Taipale H. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. *JAMA Psychiatry*. 2017;74(7):686-693. doi:10.1001/jamapsychiatry.2017.1322. Published online June 7, 2017.
- ⁵ Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies. *Journal of Clinical Psychiatry* 2013; 74(10):957
- ⁶ Rosenheck RA, Krystal JH, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *NEJM*, 2011;364:842-851
- ⁷ Fleischhacker WW, Eerdeken M, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. *J Clin Psychiatry*, 2003;64(10):1250-1257
- ⁸ Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10–24 years: a systematic analysis. *Lancet* 2011;377:2093–102.
- ⁹ Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 2012;379:2063–71.
- ¹⁰ Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *J Clin Psychiatry* 2002;63:892–909
- ¹¹ Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. *Psychiatry Res* 2005;133:129–33
- ¹² Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. *Acta Psychiatr Scand* 2007;115:260-267
- ¹³ Assisted Outpatient Treatment: Myth vs. Reality. Treatment Advocacy Center. <http://www.treatmentadvocacycenter.org/fixing-the-system/features-and-news/1403-myth-vs-reality>
- ¹⁴ Ridgely SM, Borum R, Petrila J. The Effectiveness of Involuntary Outpatient Treatment: Empirical Evidence and the Experience of Eight States. RAND Health, RAND Institute for Civil Justice. 2001. <http://www.rand.org/>
- ¹⁵ Stettin B, Geller J, Ragosta K, Cohen K, Ghowrwal J. Mental Health Commitment Laws: A Survey of the States. Treatment Advocacy Center. February 2014.
- ¹⁶ Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA15-4927, NSDUH Series H-50). Center for Behavioral Health Statistics and Quality. www.samhsa.gov/data. 2015. Accessed November 1, 2017.
- ¹⁷ Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. *Therapeutic Advances in Psychopharmacology* 2014, Vol. 4(5) 198– 219 DOI: 10.1177/ 2045125314540297
- ¹⁸ Stettin B, Geller J, Ragosta K, Cohen K, Ghowrwal J. Mental Health Commitment Laws: A Survey of the States. Treatment Advocacy Center. February 2014
- ¹⁹ Gerlach, 1995] Gerlach, J. (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. *Int Clin Psychopharmacol* 9(Suppl. 5): 17–20.
- ²⁰ Remington, G. and Adams, M. (1995) Depot neuroleptic therapy: clinical considerations. *Can J Psychiatry* 40: S5–S11
- ²¹ NICE (2009) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update). *NICE Clinical Guidelines* No. 82. London: National Institute for Health and Care Excellence
- ²² Waddell, L. and Taylor, M. (2009) Attitudes of patients and mental health staff to antipsychotic longacting injections: systematic review. *Br J Psychiatry* Suppl 195: s43–s50
- ²³ Gerlach, 1995; Remington and Adams, 1995
- ²⁴ Walburn, J., Gray, R., Gournay, K., Quraishi, S. and David, A. (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. *Br J Psychiatry* 179: 300–307;
- ²⁵ De la Gándara et al. 2009 De la Gándara, J., San Molina, L., Rubio, G., Rodriguez-Morales, A, Hidalgo Borrajo, R. and Burón, J. (2009) Experience with injectable long acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. *Expert Rev Neurother* 9: 1463–1474.;
- ²⁶ Gabel et al. 2010; Kane et al. 2010 Kane, J., Detke, H., Naber, D., Sethuraman, G., Lin, D., Bergstrom, R. et al. (2010) Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *Am J Psychiatry* 167: 181–189.
- ²⁷ Dencker, S. (1984) The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. *J Clin Psychiatry* 45: 22–27; Marder et al. 1989 Marder, S., Hubbard, J., Van Putten, T. and Midha, K. (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. *Psychopharmacology* 98: 433–439

- ²⁸ Waddell, L. and Taylor, M. (2009) Attitudes of patients and mental health staff to antipsychotic longacting injections: systematic review. *Br J Psychiatry Suppl* 195: s43-s50
- ²⁹ Rocca, P., Sandei, L., Bava, I. and Frieri, T. (2013) Risperidone long-acting injection in the treatment of first episode schizophrenia. *Curr Psychopharmacol* 2: 29-36.
- ³⁰ McEvoy, J. (2006) Risks versus benefits of different types of long-acting injectable antipsychotics. *J Clin Psychiatry* 67(Suppl. 5): 15-18
- ³¹ Olfson, M., Mechanic, D., Hansell, S., Boyer, C. and Walkup, J. (1999) Prediction of homelessness within three months of discharge among inpatients with schizophrenia. *Psychiatr Serv* 50: 667-673
- ³² Peusken, J., Mertens, C., Kusters, J. and Detraux, J. (2010a) Long acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia adherence registry (eSTAR): an observational study. *Acta Psychiatr Belg* 110: 34-46.]
- ³³ Pandarakalam, J. (2003) The long-acting depot antipsychotic drugs. *Hosp Med* 64: 603-608
- ³⁴ - Janssen Connect. <https://www.janssenconnect.com/access-care-transitions/resources>;
 - Otsuka/ Lundbeck <http://www.assure.com/hcp/abilifymaintena/>;
 - Alkermes <https://www.aristada.com/care-support-for-patients>;
 - Lilly <https://www.zyprexareprevvprogram.com/public/Default.aspx>
- ³⁵ Heres et al. 2007; Remington and Adams, 1995 Remington, G. and Adams, M. (1995) Depot neuroleptic therapy: clinical considerations. *Can J Psychiatry* 40: S5-S11;
- ³⁶ Knox et al. 2004 Knox, E. and Stimmel, G. (2004) Clinical review of a long-acting, injectable formulation of risperidone. *Clin Ther* 26: 1994-2002
- ³⁷ Heres, S., Schmitz, F., Leucht, S. and Pajonk, F. (2007) The attitude of patients towards antipsychotic depot treatment. *Int Clin Psychopharmacol* 22:275-282
- ³⁸ Gerlach, 1995
- ³⁹ Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. *Psychiatr Clin North Am* 2007;30:437-52
- ⁴⁰ Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. *J Clin Psychiatry* 2012;73:669-75.
- ⁴¹ McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *JAMA* 2014;311:1978-87
- ⁴² Goff DC. Maintenance treatment with long-acting injectable antipsychotics: comparing old with new. *JAMA* 2014;311:1973-4.
- ⁴³ Castillo EG, Stroup TS. Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evidence-Based Mental Health Online First, published on April 8, 2015 as 10.1136/eb-2015-102086 Produced by BMJ Publishing Group Ltd Downloaded from <http://ebmh.bmj.com/> on October 26, 2017
- ⁴⁴ Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, and Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. *BMC Psychiatry* 2013, 13:340. <http://www.biomedcentral.com/1471-244X/13/340>
- ⁴⁵ Castillo EG, Stroup TS. Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evidence-Based Mental Health Online First, published on April 8, 2015 as 10.1136/eb-2015-102086 Produced by BMJ Publishing Group Ltd Downloaded from <http://ebmh.bmj.com/> on October 26, 2017
- ⁴⁶ Llorca et al. *BMC Psychiatry* 2013, 13:340 Page 15 of 17 <http://www.biomedcentral.com/1471-244X/13/340>

APPENDIX: PRICING FOR LONG-ACTING INJECTABLE ATYPICAL ANTIPSYCHOTICS

(data gathered on 10/18/17 through First Data Bank Pricing of Wholesale Cost Per Package)

DRUG	RECOMMENDED DOSE/DOSE RANGE*	AVAILABILITY	PRICING - WHOLESALE PER PACKAGE												
Abilify Maintena® (aripiprazole), Aristada® (aripiprazole lauroxil)	Schizophrenia: 400 mg monthly (Abilify Maintena®) 441 mg to 882 mg monthly or every-six-weeks (Aristada®)	300 mg Maintena® vial	\$1,478/vial												
		300 mg Maintena® syringe	\$1,478/syringe												
		400 mg Maintena® vial	\$1,971/vial												
		400 mg Maintena® syringe	\$1,971/syringe												
		441 mg Aristada® syringe	\$1,140/syringe												
		662 mg Aristada® syringe	\$1,722/syringe												
		882 mg Aristada® syringe	\$2,281/syringe												
Invega® Sustenna®, Invega® Trinza® (paliperidone)	Schizophrenia/Schizoaffective disorder: 234 mg initial IM dose, 156 mg one week later and 117 mg monthly thereafter with range of 39 to 234 mg based on tolerability and/or efficacy (Invega® Sustenna®) 273 mg to 819 mg IM every three months (Invega® Trinza®) administered after at least four months of stability Invega® Sustenna® The initial Invega® Trinza® dose should be determined as follows: <table border="1" data-bbox="321 957 997 1234"> <thead> <tr> <th data-bbox="321 957 620 1062">INVEGA SUSTENNA (PALIPERIDONE PALMITATE)* DOSE</th> <th data-bbox="620 957 997 1062">INVEGA TRINZA® (PALIPERIDONE PALMITATE) DOSE</th> </tr> </thead> <tbody> <tr> <td data-bbox="321 1062 620 1104">78 mg</td> <td data-bbox="620 1062 997 1104">273 mg</td> </tr> <tr> <td data-bbox="321 1104 620 1146">117 mg</td> <td data-bbox="620 1104 997 1146">410 mg</td> </tr> <tr> <td data-bbox="321 1146 620 1188">156 mg</td> <td data-bbox="620 1146 997 1188">546 mg</td> </tr> <tr> <td data-bbox="321 1188 620 1230">234 mg</td> <td data-bbox="620 1188 997 1230">819 mg</td> </tr> </tbody> </table>	INVEGA SUSTENNA (PALIPERIDONE PALMITATE)* DOSE	INVEGA TRINZA® (PALIPERIDONE PALMITATE) DOSE	78 mg	273 mg	117 mg	410 mg	156 mg	546 mg	234 mg	819 mg	39 mg Sustenna injection	\$397/syringe		
		INVEGA SUSTENNA (PALIPERIDONE PALMITATE)* DOSE	INVEGA TRINZA® (PALIPERIDONE PALMITATE) DOSE												
		78 mg	273 mg												
		117 mg	410 mg												
		156 mg	546 mg												
		234 mg	819 mg												
		78 mg Sustenna injection	\$795/syringe												
		117 mg Sustenna injection	\$1,192/syringe												
		156 mg Sustenna injection	\$1,590/syringe												
		234 mg Sustenna injection	\$2,385/syringe												
		273 mg Trinza injection	\$2,385/syringe												
		410 mg Trinza injection	\$3,577/syringe												
		546 mg Trinza injection	\$4,770/syringe												
819 mg Trinza injection	\$7,154/syringe														
Risperdal® Consta® (risperidone)	Schizophrenia: 25 to 50 mg IM every 2 weeks (Risperdal® Consta®) Bipolar mania: 25 to 50 mg IM every 2 weeks (Risperdal® Consta®)	12.5 mg Consta injection	\$216/syringe												
		25 mg Consta injection	\$432/syringe												
		37.5 mg Consta injection	\$648/syringe												
		50 mg Consta injection	\$865/syringe												
Zyprexa® Relprevv® (olanzapine)	Recommended dosing of Zyprexa® Relprevv® based on corresponding oral olanzapine doses: <table border="1" data-bbox="321 1524 997 1881"> <thead> <tr> <th data-bbox="321 1524 522 1692">TARGET ORAL OLANZAPINE DOSE</th> <th data-bbox="522 1524 724 1692">DOSING OF ZYPREXA RELPREVV DURING THE FIRST 8 WEEKS</th> <th data-bbox="724 1524 997 1692">MAINTENANCE DOSE AFTER 8 WEEKS OF ZYPREXA RELPREVV TREATMENT</th> </tr> </thead> <tbody> <tr> <td data-bbox="321 1692 522 1766">10 mg/day</td> <td data-bbox="522 1692 724 1766">210 mg/2 weeks or 405 mg/4 weeks</td> <td data-bbox="724 1692 997 1766">150 mg/2 weeks or 300 mg/4 weeks</td> </tr> <tr> <td data-bbox="321 1766 522 1839">15 mg/day</td> <td data-bbox="522 1766 724 1839">300 mg/2 weeks</td> <td data-bbox="724 1766 997 1839">210 mg/2 weeks or 405 mg/4 weeks</td> </tr> <tr> <td data-bbox="321 1839 522 1892">20 mg/day</td> <td data-bbox="522 1839 724 1892">300 mg/2 weeks</td> <td data-bbox="724 1839 997 1892">300 mg/2 weeks</td> </tr> </tbody> </table>	TARGET ORAL OLANZAPINE DOSE	DOSING OF ZYPREXA RELPREVV DURING THE FIRST 8 WEEKS	MAINTENANCE DOSE AFTER 8 WEEKS OF ZYPREXA RELPREVV TREATMENT	10 mg/day	210 mg/2 weeks or 405 mg/4 weeks	150 mg/2 weeks or 300 mg/4 weeks	15 mg/day	300 mg/2 weeks	210 mg/2 weeks or 405 mg/4 weeks	20 mg/day	300 mg/2 weeks	300 mg/2 weeks	210 mg Relprevv injection	\$590/vial
		TARGET ORAL OLANZAPINE DOSE	DOSING OF ZYPREXA RELPREVV DURING THE FIRST 8 WEEKS	MAINTENANCE DOSE AFTER 8 WEEKS OF ZYPREXA RELPREVV TREATMENT											
		10 mg/day	210 mg/2 weeks or 405 mg/4 weeks	150 mg/2 weeks or 300 mg/4 weeks											
		15 mg/day	300 mg/2 weeks	210 mg/2 weeks or 405 mg/4 weeks											
		20 mg/day	300 mg/2 weeks	300 mg/2 weeks											
		300 mg Relprevv injection	\$842/vial												
405 mg Relprevv injection	\$1,137/vial														